A study published in The Journal of Pathology reveals that many cancers that carry a poor prognosis express an altered form of human telomerase reverse transcriptase (hTERT), an enzyme that regulates the expression of multiple genes.
Scientists previously linked a modification called phosphorylation at a particular location on the hTERT enzyme to poor prognosis in liver and pancreatic cancers. Now the team has built on this research to show that elevated levels of this phosphorylated hTERT are common in other types of cancer as well, especially when the cancers have aggressive features.
We developed a monoclonal antibody and an automated immunostaining system to detect phosphorylated hTERT in tissue samples, thus providing a basis for the development of a novel clinical diagnostic tool to identify patients with aggressive cancer."
Yoko Matsuda, MD, PhD, Study Lead Author, Kagawa University
Source:
Journal reference:
Matsuda, Y., et al. (2022) Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs. The Journal of Pathology. doi.org/10.1002/path.5876.
Research suggests no need for yellow fever vaccine booster after initial dose